The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.
 
Kazuki Watabe
No Relationships to Disclose
 
Izumi Ohno
No Relationships to Disclose
 
Miho Sakai
No Relationships to Disclose
 
Tomoya Takahashi
No Relationships to Disclose
 
Nana Yamada
No Relationships to Disclose
 
Shodai Tohyama
No Relationships to Disclose
 
Yu Sekine
No Relationships to Disclose
 
Jihei Sugihara
No Relationships to Disclose
 
Mayu Ohuchi
No Relationships to Disclose
 
Hiroki Nagashima
No Relationships to Disclose
 
Koji Takahashi
No Relationships to Disclose
 
Kohichiro Okitsu
No Relationships to Disclose
 
Motoyasu Kan
No Relationships to Disclose
 
Hiroshi Ohyama
No Relationships to Disclose
 
Masayuki Ohtsuka
No Relationships to Disclose
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)